Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore

References

• Wang H, Naghavi M, Allen C, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the global burden of disease study 2015. The Lancet. 2016 Oct 8;388(10053):1459–1544. doi: 10.1016/s0140-6736(16)31012-1
   PubMed Web of Science ®Google Scholar
• World Health Organization [Internet]. Estimated number of new cases in 2020, liver, both sexes, all ages. 2020 [cited 2023 May 24]. Available from: https://gco.iarc.fr/today/online-analysis-treemap?v=2018&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=5&group_cancer=1&include_nmsc=1&include_nmsc_other=1&reloaded
   Google Scholar
• National Registry of Diseases Office [Internet]. Singapore Cancer Registry Annual Report 2020. 2022 [cited 2023 May 11]. Available from: https://nrdo.gov.sg/docs/librariesprovider3/default-document-library/scr-2020-annual-report_web-release.pdf?sfvrsn=e0a73b99_0
   Google Scholar
• Bray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424. doi: 10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• National University Hospital [Internet]. Hepatocellular Carcinoma. 2023 [cited 2023 Jul 19]. Available from: https://www.nuhs.edu.sg/For-Patients-Visitors/find-a-condition/Pages/Hepatocellular+Carcinoma.aspx#:~:text=%E2%80%8BThe%20most%20common%20risk,hepatitis%20and%20primary%20biliary%20cirrhosis
   Google Scholar
• Lim MS, Goh GB, Chang JP, et al. A study of 3013 cases of hepatocellular carcinoma: etiology and therapy before and during the current decade. JGH Open. 2021 Sep;5(9):1015–1018. doi: 10.1002/jgh3.12624
   PubMed Web of Science ®Google Scholar
• Colagrande S, Inghilesi AL, Aburas S, et al. Challenges of advanced hepatocellular carcinoma. World J Gastroenterol. 2016 Sep 14;22(34):7645–59. doi: 10.3748/wjg.v22.i34.7645
   PubMed Web of Science ®Google Scholar
• Lau WY, Leung TW, Lai BS, et al. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann Surg. 2001 Feb;233(2):236–241. doi: 10.1097/00000658-200102000-00013
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020 May 14;382(20):1894–905. doi: 10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Bouattour M, Mehta N, He AR, et al. Systemic treatment for advanced hepatocellular carcinoma. Liver Cancer. 2019 Oct;8(5):341–58. doi: 10.1159/000496439
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378–90. doi: 10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jan;10(1):25–34. doi: 10.1016/s1470-2045(08)70285-7
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163–1173. doi: 10.1016/s0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Gyawali B, Shimokata T, Ando M, et al. Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials†. Ann Oncol. 2017 Feb 1;28(2):246–53. doi: 10.1093/annonc/mdw549
   PubMed Web of Science ®Google Scholar
• Vogel A, Qin S, Kudo M, et al. Health-related quality of life (HRQoL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (Len) or sorafenib (sor). PCN236. Value In Health. 2017;20(9):A399–A811. doi: 10.1016/j.jval.2017.08.318
   Web of Science ®Google Scholar
• Lee HT, Lee JY, Lim H, et al. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci Rep. 2017 Jul 17;7(1):5532. doi: 10.1038/s41598-017-06002-8
   PubMed Web of Science ®Google Scholar
• Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69 Suppl3(Suppl. 3):4–10. doi: 10.1159/000088478
   Google Scholar
• Kazazi-Hyseni F, Beijnen JH, Schellens JH. Bevacizumab. Oncology. 2010;15(8):819–825. doi: 10.1634/theoncologist.2009-0317
   Google Scholar
• Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022 Apr;76(4):862–73. doi: 10.1016/j.jhep.2021.11.030
   PubMed Web of Science ®Google Scholar
• Vogel A, Martinelli E, Vogel A. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO clinical practice guidelines. Ann Oncol. 2021 Jun;32(6):801–5. doi: 10.1016/j.annonc.2021.02.014
   PubMed Web of Science ®Google Scholar
• Benson AB, D’Angelica MI, Abbott DE, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021 May 1;19(5):541–565. doi: 10.6004/jnccn.2021.0022
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration [Internet]. FDA approves tremelimumab in combination with durvalumab for unresectable hepatocellular carcinoma. 2022 [cited 2023 May 8]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-unresectable-hepatocellular-carcinoma
   Google Scholar
• Food and Drug Administration [Internet]. Opdivo (Nivolumab) Prescribing Information Leaflet. 2023 [cited 2023 Oct 11]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125554s119lbl.pdf
   Google Scholar
• Food and Drug Administration [Internet]. Keytruda (pembrolizumab) prescribing information leaflet. 2023 [cited 2023 Oct 11]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s128lbl.pdf
   Google Scholar
• Health Sciences Authority [Internet]. New drug indication approval- July 2020. 2020 [cited 2023 Jul 24]. Available from: https://www.hsa.gov.sg/announcements/new-drug-indication-approvals/new-drug-indication-approval—july-2020
   Google Scholar
• Pearce F, Lin L, Teo E, et al. Health technology assessment and its use in drug policies: Singapore. Value Health Reg Issues. 2019 May;18:176–183. doi: 10.1016/j.vhri.2018.03.007
   PubMedGoogle Scholar
• Ministry of Health [Internet]. Affordable cancer drug treatment for all. 2022 [cited 2024 Jan 29]. Available from: https://www.moh.gov.sg/docs/librariesprovider5/cancer-drug-list/moh-cancer-drug-treatment-brochure-2022-(final).pdf
   Google Scholar
• Ministry of Health [Internet]. Cancer Drug List. 2023 [cited 2023 May 8]. Available from: https://www.moh.gov.sg/home/our-healthcare-system/medishield-life/what-is-medishield-life/what-medishield-life-benefits/cancer-drug-list
   Google Scholar
• Chiang CL, Chan SK, Lee SF, et al. First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: A cost-effectiveness analysis. Cancers (Basel). 2021 Feb 24;13(5):931. doi: 10.3390/cancers13050931
   PubMed Web of Science ®Google Scholar
• Su D, Wu B, Shi L. Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib as first-line treatment of unresectable hepatocellular carcinoma. JAMA Netw Open. 2021 Feb 1;4(2):e210037. doi: 10.1001/jamanetworkopen.2021.0037
   PubMed Web of Science ®Google Scholar
• Wen F, Zheng H, Zhang P, et al. Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states. Liver Int. 2021 May;41(5):1097–104.
   PubMed Web of Science ®Google Scholar
• Phua LC, Lee SC, Ng K, et al. Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer. BMC Health Serv Res. 2020 Jun 24;20(1):581. doi: 10.1186/s12913-020-05445-6
   PubMed Web of Science ®Google Scholar
• Aziz MIA, Foo WYX, Toh CK, et al. Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore. J Med Econ. 2020 Nov;23(11):1330–9. doi: 10.1080/13696998.2020.1819822
   PubMed Web of Science ®Google Scholar
• Agency for Care Effectiveness [Internet]. Procedures and guidelines for company submissions to the agency for care effectiveness for funding consideration, version 1.3, March 2023. 2023 [cited 2023 May 5]. Available from: https://www.ace-hta.gov.sg/docs/default-source/company-led-submission/procedures-and-guidelines-for-company-submissions_v1-2_mar-2023.pdf
   Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal [Internet]. 2013 [cited 2023 May 8]. Available from: https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781
   Google Scholar
• Saiyed M, Byrnes J, Srivastava T, et al. Cost-effectiveness of lenvatinib compared with sorafenib for the first-line treatment of advanced hepatocellular carcinoma in Australia. Clin Drug Investig. 2020 Dec;40(12):1167–1176. doi: 10.1007/s40261-020-00983-7
   PubMed Web of Science ®Google Scholar
• Meyers BM, Vogel A, Marotta P, et al. The cost-effectiveness of lenvatinib in the treatment of advanced or unresectable hepatocellular carcinoma from a Canadian perspective. Canadian Journal Of Gastroenterology And Hepatology. 2021;2021:1–8. doi: 10.1155/2021/8811018
   Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health [Internet]. pan-Canadian oncology drug review final economic guidance report. Cabozantinib (Cabometyx) for hepatocellular carcinoma. 2022 [cited 2022 Feb 4]. Available from: https://cadth.ca/sites/default/files/pcodr/Reviews2020/10186CabozantinibHCC_fnEGR_NOREDACT-ABBREV_EC_22Apr2020_final.pdf
   Google Scholar
• Agency for Care Effectiveness [Internet]. Lenvatinib and sorafenib for treating advanced hepatocellular carcinoma. 2021 [cited 2023 May 8]. Available from: https://www.ace-hta.gov.sg/docs/default-source/drug-guidances/lenvatinib-and-sorafenib-for-treating-advanced-hcc-(4-jan-2022).pdf
   Google Scholar
• Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol. 2022;40(4_suppl):379–379. doi: 10.1200/JCO.2022.40.4_suppl.379
   Web of Science ®Google Scholar
• Agency for Care Effectiveness. [Internet]. Review of cancer drugs for previously treated advanced hepatocellular carcinoma. 2021 [cited 2023 May 5]. Available from: https://www.ace-hta.gov.sg/docs/default-source/drug-guidances/review-of-cancer-drugs-for-previously-treated-advanced-hepatocellular-carcinoma-(updated-19-december-2022).pdf
   Google Scholar
• Chow PK, Choo SP, Ng DC, et al. National Cancer Centre Singapore consensus guidelines for hepatocellular carcinoma. Liver Cancer. 2016 Apr;5(2):97–106. doi: 10.1159/000367759
   PubMed Web of Science ®Google Scholar
• Baltussen RMP [Internet]. WHO guide to cost-effectiveness analysis. 2003 [cited 2023 May 8]. Available from: http://apps.who.int/iris/bitstream/handle/10665/42699/9241546018.pdf;jsessionid=E83F01E14C32F4C7564DA60E45A0706A?sequence=1
   Google Scholar
• Department of Statistics Singapore [Internet]. National accounts. 2023 [cited 2023 May 5]. Available from: https://www.singstat.gov.sg/find-data/search-by-theme/economy/national-accounts/latest-data
   Google Scholar
• Quinn C, Garrison LP, Pownell AK, et al. Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. J Immunother Cancer. 2020 Jul;8(2). doi: 10.1136/jitc-2020-000648
   Web of Science ®Google Scholar
• Ananthakrishnan R, Green S, Previtali A, et al. Critical review of oncology clinical trial design under non-proportional hazards. Crit Rev Oncol Hematol. 2021 Jun;162:103350. doi: 10.1016/j.critrevonc.2021.103350
   PubMed Web of Science ®Google Scholar
• Department of Statistics Singapore [Internet]. Complete life tables for Singapore resident population, 2021-2022. 2022 [cited 2023 May 24]. Available from: https://www.singstat.gov.sg/publications/population/complete-life-table
   Google Scholar
• van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012 Jul;15(5):708–715. doi: 10.1016/j.jval.2012.02.008
   PubMed Web of Science ®Google Scholar
• Pruis SL, Aziz MIA, Pearce F, et al. Cost-effectiveness analysis of sunitinib versus interferon-alfa for first-line treatment of advanced and/or metastatic renal cell carcinoma in Singapore. Int J Technol Assess Health Care. 2019 Jan;35(2):126–133. doi: 10.1017/s0266462319000059
   PubMed Web of Science ®Google Scholar
• Agency for Care Effectiveness [Internet]. Agency for care effectiveness. Singapore healthcare resource sheet (Mar 2023). 2023 [cited 2023 May 5]. Available from: https://www.ace-hta.gov.sg/resources/process-methods
   Google Scholar
• Ministry of Health [Internet]. Fee benchmark for upper GI endoscopy with/without biopsy. TOSP code SF701I. 2023 [cited 2023 May 11]. Available from: https://www-moh-gov-sg-admin.cwp.sg/cost-financing/hospital-bills-and-fee-benchmarks-search-result/detail?Code=SF701I
   Google Scholar
• Aziz MIA, Tan LE, Tan WHG, et al. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer. J Med Econ. 2020 Sep;23(9):952–60. doi: 10.1080/13696998.2020.1775620
   PubMed Web of Science ®Google Scholar
• Qin S, Ren Z, Feng YH, et al. Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study. Liver Cancer. 2021 Jul;10(4):296–308. doi: 10.1159/000513486
   PubMed Web of Science ®Google Scholar
• Department of Statistics Singapore [Internet]. Population and Population Structure. 2023 [cited 2024 Jan 29]. Available from: https://www.singstat.gov.sg/find-data/search-by-theme/population/population-and-population-structure/latest-data
   Google Scholar
• National Institute for Health and Care Excellence [Internet]. Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma. TA666. 2020 [cited 2023 May 8]. Available from: https://www.nice.org.uk/guidance/ta666/resources/atezolizumab-with-bevacizumab-for-treating-advanced-or-unresectable-hepatocellular-carcinoma-pdf-82609262480581
   Google Scholar
• National Institute for Health and Care Excellence [Internet]. Lenvatinib for advanced, unresectable, untreated hepatocellular carcinoma [ID1089]. TA551. 2018 [Cited 2023 May 8]. Available from: https://www.nice.org.uk/guidance/ta551/documents/committee-papers
   Google Scholar
• Ikeda S, Kudo M, Izumi N, et al. Cost-effectiveness of lenvatinib in the treatment of patients with unresectable hepatocellular carcinomas in Japan: an analysis using data from Japanese patients in the REFLECT trial. Value Health Reg Issues. 2021 May;24:82–89. doi: 10.1016/j.vhri.2020.05.009
   PubMedGoogle Scholar
• Viswambaram A, Wee Y, Lim S. PMU20 is there an implicit willingness-to-pay threshold in Singapore? Value Health Reg Issues. 2020;22:22. doi: 10.1016/j.vhri.2020.07.378
   Google Scholar
• Griffiths E. NICE’s criteria for end-of-life therapies: is there a fourth hurdle to overcome? PHP282. Value Health. 2016;19(7):A489. doi: 10.1016/j.jval.2016.09.825
   Web of Science ®Google Scholar
• Bovenberg J, Penton H, Buyukkaramikli N. 10 years of end-of-life criteria in the United Kingdom. Value Health. 2021 May;24(5):691–8. doi: 10.1016/j.jval.2020.11.015
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence [Internet]. Appraising life-extending, end of life treatments. 2009 [cited 2023 May 10]. Available from: https://www.nice.org.uk/guidance/gid-tag387/documents/appraising-life-extending-end-of-life-treatments-paper2
   Google Scholar
• Health Sciences Authority [Internet]. New drug approvals - August 2023. 2023 [cited 2024 Feb 6]. Available from: https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals—august-2023
   Google Scholar